Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 05/10/21
Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual MeetingGlobeNewsWire • 04/27/21
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/08/21
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsGlobeNewsWire • 03/18/21
Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In USBenzinga • 03/05/21
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry DiseaseGlobeNewsWire • 03/05/21
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular TargetPRNewsWire • 02/25/21
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021GlobeNewsWire • 01/13/21
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type IGlobeNewsWire • 12/17/20
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/08/20